Scientific Frontline: "At a Glance" Summary
- Main Discovery: An antibody-based immunotherapy successfully reduced atherosclerotic plaque volume and inflammation in murine models, demonstrating a novel ability to clear existing arterial obstructions rather than simply preventing new growth.
- Methodology: Researchers utilized single-cell profiling on human coronary arteries to identify "modulated smooth muscle cells" expressing fibroblast activation protein (FAP). They then engineered a bispecific T cell engager (BiTE) molecule to specifically target these FAP-expressing cells, directing the host immune system to destroy them.
- Key Data: The study analyzed over 150,000 cells from 27 human coronary arteries to isolate the specific molecular targets. In mouse models, the administration of the BiTE therapy significantly decreased total plaque burden and improved plaque stability compared to untreated controls.
- Significance: Unlike standard statin therapies that primarily prevent disease progression by lowering cholesterol, this approach actively eliminates established plaque and associated inflammatory cells, potentially offering a solution for patients who remain at high risk of heart attack despite controlled lipid levels.
- Future Application: This technology supports the development of precision medicine for advanced coronary artery disease and enables the use of PET/CT imaging tracers to distinguish between stable and unstable, rupture-prone plaques in clinical settings.
- Branch of Science: Cardiology and Immunology
- Additional Detail: The targeted modulated smooth muscle cells are functionally distinct from healthy structural cells, as they migrate to artery walls and secrete signals that recruit inflammatory immune cells, directly driving lesion instability.





.jpg)










.jpg)


